Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 9,301–9,325 of 27,380 studies, newest first · page 373 of 1096.

January 2022 25

  1. 2022-01-20

    Relational Design for Dementia and Job Significance (ReDeSign): Study protocol for a randomized controlled trial of an online dementia training for retail workers

    ✓ Peer-reviewed Risk factors Contemporary Clinical Trials Communications

    Key finding: ReDeSign provides dementia training to convenience store workers and contributes to developing an inclusive community for people with dementia.

  2. 2022-01-20

    Tau interactome maps synaptic and mitochondrial processes associated with neurodegeneration

    ✓ Peer-reviewed Lewy body dementia Cell

    Key finding: We showed that FTD mutations impair bioenergetics and markedly diminished Tau's interaction with mitochondria proteins, which were downregulated in AD brains of multiple cohorts and correlated with disease severity.

  3. 2022-01-20

    Is more always better? Dose effect in a multidomain intervention in older adults at risk of dementia

    ✓ Peer-reviewed Treatments Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: The non-linear function indicates that a higher dose is not necessarily better in multidomain interventions. +2 more findings

  4. 2022-01-19

    Home, but Not Homebound: A Prospective Analysis of Persons Living With Dementia

    ✓ Peer-reviewed Health systems and care delivery Journal of the American Medical Directors Association

    Key finding: 20% of individuals with newly identified dementia were homebound and this group was more functionally impaired, medically complex, and socioeconomically disadvantaged as compared to the non-homebound. +4 more findings

  5. 2022-01-19

    Hypocretins (orexins): The ultimate translational neuropeptides

    ✓ Peer-reviewed Risk factors Journal of internal medicine

    Key finding: Circuit neuroscience findings suggest that the Hcrt system is a hub that integrates diverse inputs modulating arousal (e.g., circadian rhythms, metabolic status, positive and negative emotions) and conveys this information to multiple output regions. +1 more finding

  6. 2022-01-19

    Air Pollution and the Risk of Parkinson's Disease: A Review

    ✓ Peer-reviewed Risk factors Movement disorders : official journal of the Movement Disorder Society

    Key finding: Recent epidemiological studies have found that exposure to air pollution is associated with an increased risk for development of Parkinson's disease, although not all results are uniform. +1 more finding

  7. 2022-01-17

    Long-term effects of PM2.5 components on incident dementia in the northeastern United States

    ✓ Peer-reviewed Risk factors The Innovation

    Key finding: Penalized spline models indicated that dementia incidence increased linearly with elevated black carbon concentrations, whereas the incidence of dementia was only elevated significantly following sulfate concentrations above ∼2 μg/m 3 . +1 more finding

  8. 2022-01-17

    A human-based multi-gene signature enables quantitative drug repurposing for metabolic disease

    ✓ Peer-reviewed Drug development eLife

    Key finding: Drug repurposing (DR) may identify treatments for IR; however, barriers include uncertainty whether in vitro transcriptomic assays yield quantitative pharmacological data, or how to optimise assay design to best reflect in vivo human disease. +4 more findings

  9. 2022-01-15

    Human apolipoprotein E isoforms are differentially sialylated and the sialic acid moiety in ApoE2 attenuates ApoE2-Aβ interaction and Aβ fibrillation

    ✓ Peer-reviewed Genetics Neurobiology of disease

    Key finding: In the present study, we found that the sialylation profiles of ApoE protein in the human brain are significantly different among the three isoforms, with ApoE2 exhibiting the most abundant sialic acid modification whereas ApoE4 had the least. +4 more findings

  10. 2022-01-15

    Dynamic changes of CSF sPDGFRβ during ageing and AD progression and associations with CSF ATN biomarkers

    ✓ Peer-reviewed Biomarkers Molecular neurodegeneration

    Key finding: Our results suggest that pericyte injury contributes to AD progression in the early stage in an Aβ-independent pathway. +3 more findings

  11. 2022-01-15

    Progranulin as a therapeutic target in neurodegenerative diseases

    ✓ Peer-reviewed Inflammation and the immune system Trends in pharmacological sciences

    Key finding: It regulates lysosomal biogenesis, inflammation, repair, stress response, and aging. +3 more findings

  12. 2022-01-15

    Soluble TREM2: Innocent bystander or active player in neurological diseases?

    ✓ Peer-reviewed TREM2 and immune genetics Neurobiology of disease

    Key finding: TREM2 has attracted a lot of interest in the past decade for its critical role in modulating microglia functions under homeostatic conditions and in neurodegenerative diseases. +3 more findings

  13. 2022-01-14

    Estimated Annual Spending on Aducanumab in the US Medicare Program

    ✓ Peer-reviewed Costs and economics JAMA health forum

    Key finding: This cross-sectional study examines upper bound and lower bound annualized Medicare costs for administering aducanumab to beneficiaries with the approved indications of mild cognitive impairment or mild dementia.

  14. 2022-01-14

    Gut microbiota in patients with Alzheimer's disease spectrum: a systematic review and meta-analysis

    ✓ Peer-reviewed Disease mechanisms Aging

    Key finding: Patients with AD spectrum demonstrated altered GM abundance, which was differentially mediated by countries and clinical stages. +4 more findings

  15. 2022-01-14

    Co-design of a Smartphone App for People Living With Dementia by Applying Agile, Iterative Co-design Principles: Development and Usability Study

    ✓ Peer-reviewed Cognitive tests and assessment JMIR mHealth and uHealth

    Key finding: We found patient and care partner input to be critical throughout the development process for early identification of design and usability issues and for identifying solutions not previously considered by our research team. +1 more finding

  16. 2022-01-14

    Long Non-coding RNA: Insight Into Mechanisms of Alzheimer's Disease

    ✓ Peer-reviewed Inflammation and the immune system Frontiers in molecular neuroscience

    Key finding: Increasing evidence has revealed a vital role of non-coding RNAs (ncRNAs), especially long non-coding RNAs (lncRNAs), in AD.

  17. 2022-01-13

    Metabolic Syndrome, Cognitive Impairment and the Role of Diet: A Narrative Review

    ✓ Peer-reviewed Risk factors Nutrients

    Key finding: MetS and cognitive decline share common cardiometabolic pathways as MetS components can trigger cognitive impairment. +4 more findings

  18. 2022-01-13

    RETRACTED ARTICLE: Artificial intelligence in disease diagnosis: a systematic literature review, synthesizing framework and future research agenda

    ⚠ Retracted — do not rely on it Digital health tools Journal of ambient intelligence and humanized computing

    Key finding: Based on the study of different articles on disease diagnosis, the results are also compared using various quality parameters such as prediction rate, accuracy, sensitivity, specificity, the area under curve precision, recall, and F1-score.

    Scored 39 on our rubric, shown as 16: non-peer-reviewed sources are capped at 16. See the breakdown.

  19. 2022-01-13

    Monthly At-Home Computerized Cognitive Testing to Detect Diminished Practice Effects in Preclinical Alzheimer's Disease

    ✓ Peer-reviewed Cognitive tests and assessment Frontiers in aging neuroscience

    Key finding: Overall, individuals improved on all C3 measures over 12 months (β = 0.23, 95% CI [0.21-0.25], p < 0.001), but improvement over the first 3 months was greatest (β = 0.68, 95% CI [0.59-0.77], p < 0.001), suggesting stronger PE over initial repeated exposures. +3 more findings

  20. 2022-01-13

    Comparison of serum neurodegenerative biomarkers among hospitalized COVID-19 patients versus non-COVID subjects with normal cognition, mild cognitive impairment, or Alzheimer's dementia

    ✓ Peer-reviewed Biomarkers Alzheimer's & dementia : the journal of the Alzheimer's Association

    Key finding: Neurodegenerative biomarkers were elevated to levels observed in AD dementia and associated with encephalopathy and worse outcomes among hospitalized COVID-19 patients. +4 more findings

  21. 2022-01-13

    Association of serum 25-hydroxyvitamin D concentrations with risk of dementia among individuals with type 2 diabetes: A cohort study in the UK Biobank

    ✓ Peer-reviewed Long-term cohort studies PLoS medicine

    Key finding: However, due to the synergistic effect between diabetic pathology and neuroinflammation, and the prothrombotic profile in patients with diabetes, whether vitamin D is associated with risk of dementia among patients with diabetes is unclear. +3 more findings

  22. 2022-01-12

    Cognitive reserve as one of the determinants of the progression of Alzheimer disease

    ✓ Peer-reviewed Risk factors Geriatrie et psychologie neuropsychiatrie du vieillissement

    Key finding: To assess the validity of Yaakov Stern's theory, which postulates that the first cognitive deficits of Alzheimer disease are delayed in patients with high cognitive reserve, compared to those with low cognitive reserve, but this is subsequently associated with faster cognitive decline when cerebral lesions have reached a certain degree of severity. +2 more findings

  23. 2022-01-12

    Advance Care Planning in Neurodegenerative Disorders: A Scoping Review

    ✓ Peer-reviewed End-of-life care International journal of environmental research and public health

    Key finding: In conclusion, more research is needed to investigate barriers and facilitators of ACP uptake, as well as to develop/test interventions in almost all the neurodegenerative disorders.

  24. 2022-01-12

    MIND diet and the risk of dementia: a population-based study

    ✓ Peer-reviewed Long-term cohort studies Alzheimer's research & therapy

    Key finding: Adherence to the Mediterranean-DASH Intervention for Neurodegenerative Delay (MIND) diet has been linked to a decreased risk of dementia, but reverse causality and residual confounding by lifestyle may partly account for this link. +3 more findings

  25. 2022-01-12

    Cost-Effectiveness and Value-Based Pricing of Aducanumab for Patients With Early Alzheimer Disease

    ✓ Peer-reviewed Drug development Neurology

    Key finding: Aducanumab was granted accelerated approval with a conflicting evidence base, near-unanimous Food and Drug Administration Advisory Committee vote to reject approval, and a widely criticized launch price of $56,000 per year. +3 more findings

Browse the library by subject, with the full score breakdown →